267 related articles for article (PubMed ID: 11716838)
1. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
Hirose R; Okumura H; Yoshimatsu A; Irie J; Onoda Y; Nomoto Y; Takai H; Ohno T; Ichimura M
Eur J Pharmacol; 2001 Nov; 431(1):17-24. PubMed ID: 11716838
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
3. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Wallis RM; Corbin JD; Francis SH; Ellis P
Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
[TBL] [Abstract][Full Text] [Related]
5. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello V
Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
[No Abstract] [Full Text] [Related]
6. Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta.
Mochida H; Inoue H; Takagi M; Noto T; Yano K; Kikkawa K
Eur J Pharmacol; 2002 Apr; 440(1):45-52. PubMed ID: 11959087
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Vemulapalli S; Watkins RW; Chintala M; Davis H; Ahn HS; Fawzi A; Tulshian D; Chiu P; Chatterjee M; Lin CC; Sybertz EJ
J Cardiovasc Pharmacol; 1996 Dec; 28(6):862-9. PubMed ID: 8961086
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859.
Qiu Y; Bhattacharjee S; Kraft P; John TM; Craig E; Haynes-Johnson D; Guan J; Jiang W; Macielag M; Sui Z; Clancy J; Lundeen S
Eur J Pharmacol; 2003 Jul; 472(1-2):73-80. PubMed ID: 12860475
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
[TBL] [Abstract][Full Text] [Related]
10. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
Dunkern TR; Hatzelmann A
Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
[TBL] [Abstract][Full Text] [Related]
11. cGMP-phosphodiesterase antagonists inhibit Ca2+-influx in Dictyostelium discoideum and bovine cyclic-nucleotide-gated-channel.
Lusche DF; Kaneko H; Malchow D
Eur J Pharmacol; 2005 Apr; 513(1-2):9-20. PubMed ID: 15878705
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase-5 isoforms: differential cyclic guanyl monophosphate binding and cyclic guanyl monophosphate catalytic activities, and inhibitory effects of sildenafil and vardenafil.
Lin G; Xin ZC; Lue TF; Lin CS
J Urol; 2006 Sep; 176(3):1242-7. PubMed ID: 16890733
[TBL] [Abstract][Full Text] [Related]
13. FR226807: a potent and selective phosphodiesterase type 5 inhibitor.
Hosogai N; Hamada K; Tomita M; Nagashima A; Takahashi T; Sekizawa T; Mizutani T; Urano Y; Kuroda A; Sawada K; Ozaki T; Seki J; Goto T
Eur J Pharmacol; 2001 Oct; 428(2):295-302. PubMed ID: 11675048
[TBL] [Abstract][Full Text] [Related]
14. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
15. Cyclic GMP phosphodiesterase-5: target of sildenafil.
Corbin JD; Francis SH
J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772
[No Abstract] [Full Text] [Related]
16. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
17. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.
Gibson A
Eur J Pharmacol; 2001 Jan; 411(1-2):1-10. PubMed ID: 11137852
[TBL] [Abstract][Full Text] [Related]
19. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
20. The cyclic GMP-specific phosphodiesterase inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome reaction.
Lefièvre L; De Lamirande E; Gagnon C
J Androl; 2000; 21(6):929-37. PubMed ID: 11105920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
